SPL 4.76% 10.0¢ starpharma holdings limited

The Pipeline, page-17

  1. 54 Posts.
    I am biology scientist. If the DEPs platform is successful, it may be the next generation of whole targeted therapy drug.
    Waiting for full result of stage 1
    PS: below is best article of this platform, the result of starphama is reproducible, they dont "cook".
    https://www.nature.com/articles/srep23179.pdf
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.